LYMPHOMA, NON-HODGKIN
Clinical trials for LYMPHOMA, NON-HODGKIN explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, NON-HODGKIN trials appear
Sign up with your email to follow new studies for LYMPHOMA, NON-HODGKIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New lymphoma drug trial halted early
Disease control TerminatedThis study tested a new drug, PF-08046045, in people with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, and only 22 people took part.
Matched conditions: LYMPHOMA, NON-HODGKIN
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 26, 2026 11:41 UTC
-
Promising combo for tough lymphoma hits early hurdle
Disease control TerminatedThis early-phase trial tested a combination of two drugs, tazemetostat and venetoclax, in people with Non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goals were to find the safest dose and understand side effects. Only 3 people took part befor…
Matched conditions: LYMPHOMA, NON-HODGKIN
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 26, 2026 11:40 UTC